| Peter Carignan |
Peter Carignan currently works at Arrowhead Pharmaceuticals, Inc., as Vice President-Clinical Operations from 2022. |
| Patrick C. O'brien |
Patrick C. O'brien is the founder of Obrien Gould Pllc, which was founded in 2010. He is currently the COO, Secretary & Chief Compliance Officer at Arrowhead Pharmaceuticals, Inc. since 2014. Previously, he worked as the Vice President-Law at Johnson & Johnson from 2001 to 2009, and as a Partner at Holland & Knight LLP. He also served as Regulatory Counsel at the US Food & Drug Administration. From 2001 to 2009, he held the position of Vice President-Law at Janssen Biotech, Inc. From 2012 to 2014, he was the Group Vice President-Law at Shire, Inc. Additionally, he worked as a Partner at Burke Oneil LLC from 2009 to 2010. Dr. O'brien completed his undergraduate, graduate, and doctorate degrees at the University of Arizona. |
| Jane Davidson |
Jane Davidson is currently working as the Vice President-Human Resources at Arrowhead Pharmaceuticals, Inc. Previously, she worked as the Vice President-Shareholder Relations at Acacia Research Corp. from 1995 to 2000. Ms. Davidson completed her undergraduate degree at Hood College and her graduate degree at Antioch University. |
| James C. Hamilton |
James C. Hamilton is the founder of NanoValent Pharmaceuticals, Inc. (founded in 2005). He is currently the Chief Discovery & Translational Medicine at Arrowhead Pharmaceuticals, Inc. He was formerly the Chief Executive Officer at Calando Pharmaceuticals, Inc. Dr. Hamilton received his undergraduate degree from Miami University and his MBA and doctorate degrees from The Ohio State University. |
| Kenneth Allen Myszkowski |
Kenneth Allen Myszkowski is currently the Chief Financial Officer at Arrowhead Pharmaceuticals, Inc. He previously worked as a Finance Director & Controller at NanoInk, Inc. and Delphion, Inc. He also held various financial positions at Primary Energy Ventures LLC, FMC Corp., Premark International, Inc., EPCOR Utilities, Inc., and Arthur Andersen LLP. Additionally, he worked as a Controller at Broadwind, Inc., Epcor USA Holdings LLC, and Capital Power Operations (USA), Inc. Myszkowski received his undergraduate degree from the University of Illinois and his MBA from The University of Chicago Booth School of Business. |
| Tracie Oliver |
Tracie Oliver is the Chief Commercial Officer at Arrowhead Pharmaceuticals, Inc. She previously worked as the Head-Ortho Biotech Nephrology Business Unit at Johnson & Johnson. She was also the Global Head-New Product Planning & Device Strategy at Shire Pharmaceuticals, Inc. from 2016 to 2017. Ms. Oliver has an undergraduate and graduate degree from Queen's University and an MBA from The Schulich School of Business. |
| Bruce D. Given |
Bruce D. Given currently works at Vapogenix, Inc., as Director, Pulmotect, Inc., as Director, Arrowhead Pharmaceuticals, Inc., as Chief Medical Scientist from 2024, InCube Venture Partners LLC, as Board of Advisor, and Gauge Capital LLC. Dr. Given also formerly worked at Encysive Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2002 to 2011, Leonardo BioSystems, Inc., as Chief Executive Officer from 2010 to 2014, ICON plc, as Chairman from 2010 to 2013, SemBioSys Genetics, Inc., as Director in 2012, Calando Pharmaceuticals, Inc., as Director from 2010 to 2014, BioHouston, Inc., as Director, Johnson & Johnson, as President-International, Arrowhead Pharmaceuticals, Inc., as COO, Head-Research & Development, Ortho-Clinical Diagnostics, Inc., as President-International, Janssen Pharmaceutica NV, as Group Vice President & Head-US Marketing, and Bruce Given Consulting, as President. Dr. Given received his undergraduate degree from Colorado State University and doctorate degree from Pritzker School of Medicine. |
| Douglass B. Given |
Founder of VIA Pharmaceuticals, Inc. and G5 Partners, LLC, Douglass B. Given is a businessperson who has been at the head of 8 different companies and presently holds the position of Chairman for Arrowhead Pharmaceuticals, Inc., Chairman for Medical Excellence, Inc., Chairman for Akiri, Inc., Managing Partner at G5 Partners, LLC, Advisory Board Member at Stanford Institute for Economic Policy Research, Advisory Board Member at Stanford Medicine, Advisory Board Member at Houston Methodist Research Institute and Managing Partner at Health2047 Capital Partners LLC. Douglass B. Given is also Member of The University of Chicago Medical Center, Advisory Board Member at Johns Hopkins Bloomberg School of Public Health and Advisory Board Member at The University of Chicago Department of Medicine and on the board of 5 other companies.
In his past career Douglass B. Given held the position of Chairman for VIA Pharmaceuticals, Inc. and Chairman at VIA Pharmaceuticals, Inc. (a subsidiary of VIA Pharmaceuticals, Inc.), President, Chief Executive Officer & Director at Poniard Pharmaceuticals, Inc., Partner-Investment & General at Bay City Capital LLC, Medical Advisor at Eli Lilly & Co., Director at Health2047, Inc., Chief Technology Officer & Senior Vice President at Mallinckrodt, Inc.(Old), Vice President at Monsanto Co., Principal at The General Hospital Corp., Vice President-Research Laboratories at G.D. Searle & Co., Inc., Vice President of Schering-Plough Research Institute and Principal at Harvard Medical School.
Dr. Given received a doctorate from The University of Chicago and an MBA from The Wharton School of the University of Pennsylvania. |
| Christopher Richard Anzalone |
Christopher Richard Anzalone was the founder of Benet Group LLC, where he served as the Chief Executive Officer. He founded the company in 2005. Dr. Anzalone is also the founder of Nanotope, Inc. Currently, Dr. Anzalone holds multiple positions. Since 2007, he has been the President, Chief Executive Officer & Director at Arrowhead Pharmaceuticals, Inc. He is also a Director at Unidym, Inc., Ablaris Therapeutics, Inc., Tego Biosciences Corp., and Arrowhead Madison, Inc. In the past, Dr. Anzalone held positions as the Chief Executive Officer of NanoInk, Inc. and Chairman & Chief Executive Officer of Calando Pharmaceuticals, Inc. He also served as a Director at Roche Madison, Inc., Kronos Bio, Inc., and Vir Biotechnology, Inc. From 1999 to 2003, he was a Partner at Galway Partners LLC. Dr. Anzalone obtained a doctorate degree from the University of California, Los Angeles and an undergraduate degree from Lawrence University. |
| Victoria Vakiener |
Victoria Vakiener is an Independent Director at Arrowhead Pharmaceuticals, Inc. and Chimerix, Inc. She previously worked as Vice President at Janssen Pharmaceuticals, Inc., Chief Commercial Officer at Epizyme, Inc., and Vice President-Oncology Marketing at Janssen Oncology, Inc. She completed her undergraduate degree at Albright College. |
| Mauro Ferrari |
Mauro Ferrari founded Nanomedical Systems, Inc. in 2007, where he worked as Director. Dr. Ferrari also founded Leonardo BioSystems, Inc. Dr. Ferrari also currently works at Dxt Pharmaceutics, as Chief Executive Officer, Arrowhead Pharmaceuticals, Inc., as Independent Director from 2010, BioHouston, Inc., as Director, the University of Washington, as Professor, and The Alliance for NanoHealth, as President. Dr. Ferrari also formerly worked at The Methodist Hospital Research Institute, as President & Chief Executive Officer from 2010 to 2019, The Methodist Hospital, as Executive Vice President from 2010 to 2019, The Ohio State University, as Professor, the University of California, Berkeley, as Professor, The University of Texas M.D. Anderson Cancer Center, as Professor, Weill Cornell Medical College, as Senior Associate Dean from 2010 to 2019, European Research Council, as President, and The University of Texas Health Science Center at Houston, as Professor. Dr. Ferrari received his doctorate degree from the University of California, Berkeley. |
| Hong Bo Lu |
Hong Bo Lu is currently a Director at Beijing PINS Medical Co., Ltd., Shanghai Rarestone Health Tech Group Co. Ltd., Ablaze Pharmaceuticals, Centrexion Therapeutics Corp., Pins Medical, Inc., Rgenta Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Avistone Pharmaceuticals, Rarestone Group, Terns Pharmaceuticals, Inc., RiboX Therapeutics, Inc., Visirna Therapeutics, Inc., Zenas Pharma, Inc., and Vivo Capital LLC. In the past, Dr. Lu served as a Managing Director at OrbiMed Advisors LLC from 2011 to 2016. She also held positions as a Director at Crown Bioscience, Inc., Crown Bioscience International, Elpiscience Biopharma Ltd., and Geneception, Inc. Additionally, she was a Director at Passage Bio, Inc. and served as an Independent Director at Avedro, Inc. from 2018 to 2019. Dr. Lu was an Independent Non-Executive Director at Turning Point Therapeutics, Inc. from 2017 to 2019 and a Non-Executive Director at Echosens SA from 2015 to 2018. She worked as a Vice President & Senior Research Analyst at Piper Sandler & Co. (Broker) from 2010 to 2011. Furthermore, she served as a Managing Partner at LAV Management Co., Ltd. from 2017 to 2020. Dr. Lu's education includes a graduate degree from Tsinghua University in 1995, a doctorate degree from the University of Washington in 2000, an undergraduate degree from Tsinghua University in 1993, and an MBA from the Haas School of Business in 2005. |
| Adeoye Y. Olukotun |
Adeoye Y. Olukotun founded VIA Pharmaceuticals, Inc. in 2004, where he worked as Chief Medical Officer from 2004 to 2008 and CR Strategies LLC in 2000, where he is working as Chief Executive Officer from 2000. Dr. Olukotun also currently works at Electrophysiology Research Foundation, as Chief Executive Officer & Trustee, Arrowhead Pharmaceuticals, Inc., as Independent Director from 2020, and Tonix Pharmaceuticals Holding Corp., as Independent Director from 2018. Dr. Olukotun also formerly worked at Abcentra, Inc., as Chief Executive Officer from 2006 to 2013, Epigen Pharmaceuticals, Inc., as President & Chief Executive Officer from 2014 to 2018, Cardio Vax LLC, as Vice Chairman from 2012 to 2016, BioClinica, Inc., as Independent Director from 2011 to 2013, Nordion (Canada), Inc., as Director in 2010, Neusentis, Inc., as Director, SemBioSys Genetics, Inc., as Director in 2007, Milestone Pharmaceuticals, Inc., as Director, MDS Nordion, Inc., as Director, BioMedical Systems Corp., as Director, D&R Greenway Land Trust, Inc., as Director, Diadexus, Inc., as Independent Director from 2013 to 2015, Genesis Unicorn Capital Corp., as Director, Chief Executive & Technology Officer, Bristol Myers Squibb Co., as Vice President, Mallinckrodt, Inc.(Old), as Vice President-Medical & Regulatory Affairs from 1996 to 2000, and Esperion Therapeutics, Inc., as Chief Medical Officer & SVP-Regulatory Affairs from 2001 to 2004. Dr. Olukotun received his doctorate degree in 1973 from Albert Einstein College of Medicine, Inc., graduate degree in 1983 from Harvard T.H. Chan School of Public Health, and undergraduate degree in 1969 from UNC School of Law. |
